10
Participants
Start Date
June 20, 2025
Primary Completion Date
August 20, 2025
Study Completion Date
September 11, 2025
PF-07054894
"Cohort 1 Period 1 - Oral \[cyclobutenyl-14C\]PF-07054894 under fasted state. Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose.~Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose."
PF-07054894
Cohort 2 Period 1 - Oral \[Methyl-14C\]PF-07054894 under fasted state.
ICON, Groningen
Lead Sponsor
Pfizer
INDUSTRY